REVO BIOLOGICS, INC. FORM OF [DIRECTOR][OFFICER] INDEMNIFICATION AGREEMENTIndemnification Agreement • June 25th, 2014 • rEVO Biologics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of by and between rEVO Biologics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • June 25th, 2014 • rEVO Biologics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is between rEVO Biologics, Inc., a Delaware corporation (the “Company”), and James Streisand (the “Executive”) and is made effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “IPO”), provided the IPO is consummated prior to April 2, 2015 (the “Effective Date”).
ACCESS AND INFORMATION AGREEMENTAccess and Information Agreement • June 25th, 2014 • rEVO Biologics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Access and Information Agreement (the “Agreement”) is effective as of June 25, 2014, by and between Laboratoire français du Fractionnement et des Biotechnologies, a French Corporation (“LFB”), and rEVO Biologics, Inc., a Delaware corporation (the “Company,” with each of LFB and the Company a “Party” and together, the “Parties”).
USE AND OCCUPANCY AGREEMENTUse and Occupancy Agreement • June 25th, 2014 • rEVO Biologics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Use and Occupancy Agreement (“Agreement”) is entered into this 31st day of March, 2014, by and LFB USA, INC. (“LFB”) and REVO BIOLOGICS, INC. with an address of 175 Crossing Boulevard, Framingham, Massachusetts (“Revo”).
PAYMENT REIMBURSEMENT AGREEMENTPayment Reimbursement Agreement • June 25th, 2014 • rEVO Biologics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS PAYMENT REIMBURSEMENT AGREEMENT (this “Agreement”) is effective as of March 31, 2014 (the “Effective Date”), by and between rEVO Biologics, Inc., a Delaware corporation, having its principal place of business located at 175 Crossing Boulevard, Framingham, Massachusetts, 01702 (“rEVO”), and LFB USA, Inc., a Delaware corporation, having its principal place of business located at 175 Crossing Boulevard, Framingham, Massachusetts, 01702 (“LFB USA”). Each of rEVO and LFB USA may be referred to herein as a “Party” or collectively as the “Parties.”
